Chronix Biomedical

Oncocyte Corporation entered a definitive agreement to acquire Chronix Biomedical, including its intellectual property and technology for blood-based immune therapy monitoring and transplant rejection testing. The deal includes Chronix's development team and lab operations in Germany.